A Phase 3 interventional study of ISV-305 and Vehicle in Inflammation and Pain Associated With Cataract Surgery, sponsored by Sun Pharmaceutical Industries Limited. Completed at 1 site in United States. Open to participants aged 17 Years and older. Per ClinicalTrials.gov, last updated 2021-11-19.
Sponsored by Sun Pharmaceutical Industries Limited · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing dexamethasone in Inflammation — 1 open to participants now, 2 under way, 2 of them phase 3. Dexamethasone · Inflammation.
Among the 14 studies testing dexamethasone in Inflammation, this one is the 6th largest by enrollment, is one of 2 that started in 2018, is one of 4 in phase 3, and was the 5th registered.
3,541 studies on the registry are indexed under Inflammation; 645 are open to participants now.
Browse Inflammation studies →1 of the 14 studies testing dexamethasone in Inflammation is open now, in 1 country. Recruiting first, the newest first:
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · Sites in Italy
Ages 18+
By country, each count listing its studies:
Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 461 Inflammation studies recruiting now, 174 (38%) set no upper age limit and 206 (45%) stop at 75 or younger; 56 take children under 18; 165 take healthy volunteers.
This study: 17 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 6 · Phase 4 4
First in 2007; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 246 is above the median of 50 across 2,581 interventional studies indexed under Inflammation.
Median enrollment 132 across the 14 interventional studies. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 14 have an industry lead sponsor. The 10 most frequent:
Sun Pharmaceutical Industries Limited is the lead sponsor of 60 studies on the registry; 5 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 22 (92%) have results posted.
Sun Pharmaceutical Industries Limited has 3 studies filed under Inflammation — fewer than ten, so there is no comparison to draw.
1 of the studies testing dexamethasone in Inflammation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05895838Phase 3Christian HassagerThe Danish Out-of-Hospital Cardiac Arrest Study | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies testing dexamethasone in Inflammation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the ocular safety, tolerability, and efficacy of ISV-305 (Dexamethasone in DuraSite® 2) compared to Vehicle in the treatment of inflammation and pain associated with cataract surgery.
The purpose of this study is to evaluate the ocular safety, tolerability, and efficacy of topical administration of ISV-305 (0.1% dexamethasone in DuraSite® 2) compared with Vehicle when dosed twice daily for 1 day prior to surgery, the day of surgery and 14 days post cataract surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.1% dexamethasone in DuraSite® 2
Drug: ISV-305
DuraSite® 2 vehicle
Other: Vehicle
Dexamethasone in DuraSite® 2 twice daily for 16 days
Vehicle twice daily for 16 days
Number of Participants With Anterior Chamber Cell Grade 0 in Study Eye at Day 15 (Last Observation Carried Forward) in the Modified Intent to Treat (mITT) Population
Biomicroscopic measurement of anterior chamber cells was conducted in the surgery eye (study eye) by the same examiner from visit to visit whenever possible. A slit-lamp biomicroscope was used at x16 magnification with a 1 x 1 mm oblique high-intensity beam. Two cell counts were summed and divided by 2 to determine an average final anterior chamber cell count. This final cell count was converted to a grade: Grades 0, 1, 2, 3, 4 were assigned for cell counts of 0, 1 to 10, 11 to 20, 21 to 50, and \> 50, respectively. If the averaged count fell between two grades, the higher grade was selected (e.g., if the two counts were 10 and 11, the average of 10.5 fell into Grade 2). Missing anterior chamber cell grade at Day 15 was imputed by last non-missing scheduled post-baseline anterior chamber cell grade assessed prior to Day 15 (last observation carried forward).
Time frame: Day 15
Number of Participants Who Achieve a Pain Score of 0 on the Visual Analog Scale (VAS) (0-100 mm Scale) for Each Post-surgical Assessment at Days 1, 8, 15, 18, and 29
Eye pain/discomfort in the study eye was evaluated at every visit except Visit 2 (Surgery; Day 0) using a VAS, scoring from 0 to 100 using a mark on a 100 mm line (0 = absent; 100 = maximum). Participants were asked to rate the feeling of the symptom in the study eye from absent to extreme by moving a slide on the side of the scale to align with images of descriptive faces.
Time frame: Day 1 to Day 29
| Milestone | ISV-305 | Vehicle |
|---|---|---|
| Started | 163 | 83 |
| Completed | 108 | 29 |
| Not completed | 55 | 54 |
| Withdrew: Adverse event | 14 | 12 |
| Withdrew: Lack of efficacy | 23 | 30 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Withdrawal by subject | 4 | 2 |
| Withdrew: Protocol violation | 5 | 2 |
| Withdrew: Surgery canceled | 6 | 2 |
| Withdrew: Other-various administrative reasons | 2 | 5 |
Biomicroscopic measurement of anterior chamber cells was conducted in the surgery eye (study eye) by the same examiner from visit to visit whenever possible. A slit-lamp biomicroscope was used at x16 magnification with a 1 x 1 mm oblique high-intensity beam. Two cell counts were summed and divided by 2 to determine an average final anterior chamber cell count. This final cell count was converted to a grade: Grades 0, 1, 2, 3, 4 were assigned for cell counts of 0, 1 to 10, 11 to 20, 21 to 50, and \> 50, respectively. If the averaged count fell between two grades, the higher grade was selected (e.g., if the two counts were 10 and 11, the average of 10.5 fell into Grade 2). Missing anterior chamber cell grade at Day 15 was imputed by last non-missing scheduled post-baseline anterior chamber cell grade assessed prior to Day 15 (last observation carried forward).
| Participants | ISV-305 | Vehicle |
|---|---|---|
| 0 (did not receive rescue therapy) | 92 | 16 |
| 0 (received rescue therapy) | 0 | 1 |
| 1 | 41 | 27 |
| 2 | 6 | 15 |
| 3 | 6 | 10 |
| 4 | 1 | 1 |
Eye pain/discomfort in the study eye was evaluated at every visit except Visit 2 (Surgery; Day 0) using a VAS, scoring from 0 to 100 using a mark on a 100 mm line (0 = absent; 100 = maximum). Participants were asked to rate the feeling of the symptom in the study eye from absent to extreme by moving a slide on the side of the scale to align with images of descriptive faces.
| Participants | ISV-305 | Vehicle |
|---|---|---|
| Pain Score of 0 on Day 1 | 87 | 29 |
| Pain Score of 0 on Day 8 | 117 | 39 |
| Pain Score of 0 on Day 15 | 119 | 41 |
| Pain Score of 0 on Day 18 | 120 | 41 |
| Pain Score of 0 on Day 29 | 120 | 45 |
Collected over Adverse events (AEs) were reported from the date of signing the consent form to the date of completion of the participant's final visit (Day 29). Ongoing AEs were followed beyond the final study visit at the discretion of the investigator, observed up to 45 days.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ISV-305 | 0/152 (0%) | 1/152 (0.7%) | 47/152 (30.9%) |
| Vehicle | 0/79 (0%) | 0/79 (0%) | 30/79 (38%) |
| Event | ISV-305 | Vehicle |
|---|---|---|
| Small intestinal obstructionGastrointestinal disorders | 1/152 | 0/79 |
| PneumoniaInfections and infestations | 1/152 | 0/79 |
| Event | ISV-305 | Vehicle |
|---|---|---|
| Conjunctival hyperaemiaEye disorders | 11/152 | 11/79 |
| Anterior chamber cellEye disorders | 18/152 | 10/79 |
| Visual acuity reducedEye disorders | 12/152 | 10/79 |
| Eye painEye disorders | 1/152 | 8/79 |
| Corneal oedemaEye disorders | 11/152 | 7/79 |
| Anterior chamber flareEye disorders | 10/152 | 7/79 |
| Intraocular pressure increasedInvestigations | 12/152 | 4/79 |
| Conjunctival oedemaEye disorders | 5/152 | 4/79 |
| Ciliary hyperaemiaEye disorders | 2/152 | 4/79 |
| Conjunctival haemorrhageEye disorders | 6/152 | 2/79 |
Demographics were summarized for the Safety Population, which included all the randomized participants who received at least one dose of study treatment.
| Age, Continuous(years) | ISV-305 | Vehicle | Total |
|---|---|---|---|
| Mean | 69.3 ± 8.84 | 71.2 ± 9.12 | 69.9 ± 8.96 |
| Sex: Female, Male(Participants) | ISV-305 | Vehicle | Total |
|---|---|---|---|
| Female | 88 | 40 | 128 |
| Male | 64 | 39 | 103 |
| Race/Ethnicity, Customized(Participants) | ISV-305 | Vehicle | Total |
|---|---|---|---|
| African American or Black | 16 | 4 | 20 |
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 5 | 0 | 5 |
| White | 130 | 72 | 202 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Mixed | 0 | 2 | 2 |
| Other | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2018 to primary completion in Nov 2019, 22 months.
Results were first posted in Jan 2021, 1 year 1 month after primary completion.
Of 21 industry-sponsored phase 3 interventional studies under Inflammation, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 28. This study's 22 months is close to that.
Counting every sponsor, half of 68 studies reached it within 27 months; a quarter within 17 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone
Sun Pharmaceutical Industries Limited →